Form 4: Orchestra BioMed Director Chris Cleary Awarded Significant Equity Compensation

Orchestra BioMed Holdings, Inc. Director Chris Cleary received an award of 12,422 restricted stock units and 36,797 stock options, aligning his interests with shareholders.

Summary

• Chris Cleary, a Director of Orchestra BioMed Holdings, Inc. (OBIO), was awarded 12,422 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 24, 2025.
• Each RSU represents a contingent right to receive one share of Common Stock, with a price of $0 per share at the time of award.
• Mr. Cleary also received an award of 36,797 stock options with an exercise price of $3.22 per share on the same date.
• The RSUs and stock options will vest in a single installment on the earlier of the one-year anniversary of the grant date (June 24, 2026) or the date of the Issuer's 2026 Annual Meeting of Stockholders.
• Vesting is contingent upon Mr. Cleary's continuous service to the company through the respective vesting dates.
• Following these transactions, Chris Cleary beneficially owns 22,577 shares of Common Stock and 36,797 stock options.
• The stock options have an expiration date of June 24, 2035.

Sentiment

Score: 7

Explanation: The sentiment is positive as the equity award to a director aligns their interests with shareholders, which is generally viewed favorably. There are no negative implications or risks explicitly stated in this type of filing.

Positives

• The award of restricted stock units and stock options to Director Chris Cleary aligns his financial interests directly with those of the company's shareholders, incentivizing long-term performance.
• Equity compensation at a $0 price for RSUs and a specified exercise price for options is a standard practice for director compensation, reflecting confidence in future share price appreciation.

Future Outlook

The vesting schedule for the awarded RSUs and stock options, contingent on continuous service through the one-year anniversary of the grant date or the 2026 Annual Meeting of Stockholders, indicates an expectation of continued commitment from Director Chris Cleary.

Industry Context

This Form 4 filing details a routine equity compensation award to a director, which is a common practice across various industries, including biotechnology and medical devices, to attract and retain talent and align management interests with shareholder value.

Related Party Transactions

• The award of restricted stock units and stock options to Chris Cleary, a Director of Orchestra BioMed Holdings, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The award of equity compensation to a director can be seen as positive, as it aligns the director's financial incentives with the company's long-term performance and shareholder value creation. However, it also represents potential future dilution from the issuance of new shares upon vesting and exercise.

Next Steps

• The RSUs and stock options are scheduled to vest on the earlier of June 24, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continuous service.

Key Dates

Keywords

Orchestra BioMed Holdings, OBIO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Director Compensation, Chris Cleary